Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00867113 · OUTCOME

Recurrence-free Survival up to 60 Months

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) · Source last updated 2018-03-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants with an event
Interval / dispersion
Not reported
Time frame
Baseline up to 60 months

What was measured

Recurrence-free survival assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event).

Groups in this outcome

Imatinib

All subjects received in tablet form imatinib (STI571) 400 mg once daily.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Imatinib91

Reported measurements

Subject with an event
Values in participants with an event · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imatinib9Not reportedNot reportedNot reportedNot reported
Event = disease recurrence
Values in participants with an event · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imatinib7Not reportedNot reportedNot reportedNot reported
Event=death
Values in participants with an event · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imatinib2Not reportedNot reportedNot reportedNot reported
Subjects censored
Values in participants with an event · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Imatinib82Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
    title
    Subject with an event
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Event = disease recurrence
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Event=death
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        82
    title
    Subjects censored
denoms
  1. counts
    1. group Id
      OG000
      value
      91
    units
    Participants
description
Recurrence-free survival assessment is based on the radiologic evidence and is defined as the time from the date of first dose of imatinib to the date of the first documented disease recurrence or death due to any cause (event).
groups
  1. description
    All subjects received in tablet form imatinib (STI571) 400 mg once daily.
    id
    OG000
    title
    Imatinib
param Type
NUMBER
reporting Status
POSTED
time Frame
Baseline up to 60 months
title
Recurrence-free Survival up to 60 Months
type
PRIMARY
unit Of Measure
participants with an event

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice